Drug intelligence / Profile preview

SND-106

Development stage: Preclinical
Lead developer: SND Bio
Modality: Small Molecules

Overview

SND-106 is a potent and selective small molecule inhibitor of the enzyme **Staphylococcal nuclease and tudor domain containing 1 (SND1)**, also known as p100. SND1 is a multifunctional protein that acts as a transcriptional coactivator and a component of the RNA-induced silencing complex (RISC), and it is frequently overexpressed in various cancers, including hepatocellular carcinoma, colon cancer, and breast cancer. By inhibiting the tudor domain of SND1, SND-106 disrupts its interaction with methylated proteins and its role in RNA processing and gene expression, thereby inhibiting tumor cell proliferation and survival. The compound has been primarily investigated in preclinical research settings to evaluate its potential as a targeted therapy for SND1-dependent malignancies.

Targets

NFKB2 (NF-κB2)

Beyond the preview

Go deeper on SND-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SND-106.

Explore the full profile